Search Results 7681-7690 of 34177 for oral
Exposure to synthetic oral retinoids other than palovarotene in the past 30 days prior to Part B Screening (signature of the informed consent). Concurrent ...
Subject has Chronic Obstructive Pulmonary Disease (COPD) requiring continuous home oxygen therapy or chronic outpatient oral steroid use. Subjects with non ...
Investigating tumor growth factors for oral cancer. Evaluating new methods of use for chemotherapy. Evaluating new radiation therapy regimens. Investigating ...
... Oral and throat cancer, Salivary gland cancer, Mouth cancer, Thyroid cancer, Head and neck cancer, Melanoma, Tonsil cancer, Skin cancer, Squamous cell ...
* Contraindications to the FDA-approved medications: Phentermine-Topiramate Extended Release; Oral naltrexone extended-release/bupropion extended-release ...
... (Oral Anti-Platelet) agents. In addition to exploring ED treatment patterns and success of both ischemic and bleeding risk stratification prior to definition ...
Clinical diagnosis of oropharyngeal squamous cell carcinoma or clinical diagnosis of HPV negative oral cavity cancer, to be enrolled for subgroup 1D.
... oral absorption or tolerance of ixazomib or idasanutlin including difficulty swallowing; Diarrhea > grade 1, based on the National Cancer Institute (NCI) ...
Before starting therapy the patient should be able to maintain adequate oral nutrition of ≥ 1500 calories estimated caloric intake per day and be free of ...
Stable dose (defined as no change in prescription for at least 4 weeks prior to Day 1) of NSAIDs, HCQ, MTX and/or oral corticosteroids is permitted during ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.